Bile acid sequestrants: More than simple resins

Current Opinion in Lipidology

Volumn 23, Issue 1, 2012, Pages 43-55

  Out, Carolien ^a   Groen, Albert K ^a,b   Brufau, Gemma ^a  

^a Department of Pediatrics   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

bile acid sequestrants; bile acids; energy metabolism; glucose; hypercholesterolemia

Indexed keywords

ATORVASTATIN; BILE ACID; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; MEVINOLIN; NICOTINIC ACID; PLACEBO; RESIN; SIMVASTATIN;

ABDOMINAL PAIN; BILE ACID BLOOD LEVEL; BILE ACID METABOLISM; CLINICAL EVALUATION; CONSTIPATION; ENERGY METABOLISM; GLYCEMIC CONTROL; HUMAN; METABOLIC DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PUBLISHING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANION EXCHANGE RESINS; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; CHOLESTYRAMINE RESIN; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; ENERGY METABOLISM; HUMANS;

ANIMALIA;

EID: 84855850294     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834f0ef3     Document Type: Review

References (113)

1. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89:147-191.
2. Verrips A, Hoefsloot LH, Steenbergen GC, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 2000; 123 (Pt 5):908-919. (Pubitemid 30224187)
3. Wiggins HS, Wootton ID. Studies in the bile acids. The conjugated bile salts of certain primates. Biochem J 1958; 70:349-352.
4. Hofmann AF, Eckmann L. How bile acids confer gut mucosal protection against bacteria. Proc Natl Acad Sci USA 2006; 103:4333-4334.
5. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284:1362-1365. (Pubitemid 29289663)
6. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284:1365-1368. (Pubitemid 29289664)
7. Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3:543-553. (Pubitemid 29268438)
8. Zhang J, Huang W, Qatanani M, et al. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J Biol Chem 2004; 279:49517-49522. (Pubitemid 39625839)
9. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001; 98:3369-3374. (Pubitemid 32220852)
10. Makishima M, Lu TT, Xie W, et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002; 296:1313-1316. (Pubitemid 34522785)
11. Xie W, Radominska-Pandya A, Shi Y, et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 2001; 98:3375-3380. (Pubitemid 32220853)
12. Schmidt DR, Holmstrom SR, Fon Tacer K, et al. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem 2010; 285:14486-14494.
13. Li T, Chiang JY. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol 2005; 288:G74-G84. (Pubitemid 39665222)
14. Lu TT, Makishima M, Repa JJ, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000; 6:507-515.
15. Lee YK, Moore DD. Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner. J Biol Chem 2002; 277:2463-2467. (Pubitemid 34953268)
16. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6:517-526.
17. Nitta M, Ku S, Brown C, et al. CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene. Proc Natl Acad Sci USA 1999; 96:6660-6665. (Pubitemid 29274939)
18. Out C, Hageman J, Bloks VW, et al. LRH-1 is critical for adequate upregulation of Cyp7a1 gene transcription and bile salt synthesis during bile salt sequestration. Hepatology 2011; 53:2075-2085.
19. Mataki C, Magnier BC, Houten SM, et al. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. Mol Cell Biol 2007; 27:8330-8339. (Pubitemid 350234244)
20. Lee YK, Schmidt DR, Cummins CL, et al. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol Endocrinol 2008; 22:1345-1356. (Pubitemid 351786995)
21. del Castillo-Olivares A, Gil G. Alpha 1-fetoprotein transcription factor is required for the expression of sterol 12alpha-hydroxylase, the specific enzyme for cholic acid synthesis. Potential role in the bile acid-mediated regulation of gene transcription. J Biol Chem 2000; 275:17793-17799. (Pubitemid 30430830)
22. Kim I, Ahn SH, Inagaki T, et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 2007; 48:2664-2672. (Pubitemid 350272851)
23. Houten SM, Volle DH, Cummins CL, et al. In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. Mol Endocrinol 2007; 21:1312-1323. (Pubitemid 46984739)
24. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17:1581-1591. (Pubitemid 36828786)
25. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2:217-225.
26. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282:26687-26695. (Pubitemid 47501965)
27. Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007; 282:27277-27284. (Pubitemid 47501977)
28. Yu C, Wang F, Kan M, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000; 275:15482-15489. (Pubitemid 30337280)
29. Shin DJ, Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 2009; 284:11110-11120.
30. Stroeve JH, Brufau G, Stellaard F, et al. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Lab Invest 2010; 90:1457-1467.
31. Horton JD, Goldstein JL, Brown MS. SREBPs: transcriptional mediators of lipid homeostasis. Cold Spring Harb Symp Quant Biol 2002; 67:491-498. (Pubitemid 36775545)
32. Pols TW, Noriega LG, Nomura M, et al. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis 2011; 29:37-44.
33. Herrema H, Meissner M, van Dijk TH, et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor-and liver X receptor alpha-controlled metabolic pathways in mice.Hepatology 2010; 51:806-816.
34. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99:257-273.
35. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159:1893-1900. (Pubitemid 29424709)
36. Watkins DW, Khalafi R, Cassidy MM, Vahouny GV. Alterations in calcium, magnesium, iron, and zinc metabolism by dietary cholestyramine. Dig Dis Sci 1985; 30:477-482. (Pubitemid 15051752)
37. Coronato A, Glass GB. Depression of the intestinal uptake of radio-vitamin B 12 by cholestyramine. Proc Soc Exp Biol Med 1973; 142:1341-1344.
38. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975; 16:93-98.
39. Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000; 14:681-690. (Pubitemid 32217192)
40. Hou R, Goldberg AC. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am 2009; 38:79-97.
41. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:351-364.
42. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69:313-324. (Pubitemid 14180337)
43. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III. JAMA 1988; 260:359-366.
44. Hunninghake DB, Stein EA, Bremner WF, et al. Dose-response study of colestipol tablets in patients with moderate hypercholesterolemia. Am J Ther 1995; 2:180-189.
45. Insull W, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001; 76:971-982. (Pubitemid 32946008)
46. Denke MA, Grundy SM. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med 1995; 155:393-399.
47. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233-3240. (Pubitemid 17078320)
48. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264:3013-3017.
49. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298. (Pubitemid 20364735)
50. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001; 24:467-474. (Pubitemid 32520218)
51. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110:352-360. (Pubitemid 32248724)
52. Hunninghake D, Insull W Jr, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158:407-416. (Pubitemid 32913651)
53. Moore A, Phan BA, Challender C, et al. Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. J Clin Lipidol 2007; 1:620-625. (Pubitemid 350215509)
54. Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 2006; 22:2191-2200. (Pubitemid 44789984)
55. Knopp R, Tsunehara C, Retzlaff B, et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 2006; 55:1697-1703. (Pubitemid 44830137)
56. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005; 12:306-310. (Pubitemid 41391808)
57. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005; 21:1403-1412. (Pubitemid 41368572)
58. Levy RI, Brensike JF, Epstein SE, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 1984; 69:325-337. (Pubitemid 14180338)
59. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipidlowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339:563-569.
60. Kuipers F, Stroeve JH, Caron S, Staels B. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr Opin Lipidol 2007; 18:289-297. (Pubitemid 46743053)
61. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010; 52:1455-1464.
62. Kast HR, Nguyen CM, Sinal CJ, et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001; 15:1720-1728. (Pubitemid 32939302)
63. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143:1741-1747. (Pubitemid 34415889)
64. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145:2594-2603. (Pubitemid 38686202)
65. Lambert G, Amar MJ, Guo G, et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003; 278:2563-2570. (Pubitemid 36801334)
66. Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102:731-744.
67. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113:1408-1418. (Pubitemid 39071696)
68. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2006; 185:327-330.
69. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006; 97:1198-1205.
70. Devaraj S, Autret B, Jialal I. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 2006; 98:641-643. (Pubitemid 44233461)
71. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulindependent diabetes mellitus: a short-term, double-blind, crossover trial. Ann Intern Med 1994; 121:416-422.
72. Handelsman Y, Goldberg RB, Garvey WT, et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract 2010; 16:617-628.
73. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007; 54:53-58. (Pubitemid 46481671)
74. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29:74-83. (Pubitemid 46414026)
75. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008; 168:1531-1540.
76. Goldfine AB, Fonseca VA, Jones MR, et al. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res 2010; 42:23-30.
77. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008; 168:1975-1983.
78. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31:1479-1484.
79. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007; 67:1383-1392. (Pubitemid 47026388)
80. Brinton EA. Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation. Diabetes Obes Metab 2008; 10:1004-1011.
81. Goldfine AB. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr Opin Cardiol 2008; 23:502-511.
82. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin 2007; 23:1673-1684. (Pubitemid 47122177)
83. Prawitt J, Staels B. Bile acid sequestrants: glucose-lowering mechanisms. Metab Syndr Relat Disord 2010; 8 (Suppl. 1):S3-S8.
84. Chen L, McNulty J, Anderson D, et al. Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. J Pharmacol Exp Ther 2010; 334:164-170.
85. Shang Q, Saumoy M, Holst JJ, et al. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol 2010; 298:G419-G424.
86. Beysen C, Deines KC, Tsang EL, et al. Colesevelam HCl improves glucose metabolism and increases plasma glucagon-like peptide 1 and glucosedependent insulinotropic polypeptide concentrations in subjects with type 2 diabetes. Diabetologia 2009; 52:S77.
87. Suzuki T, Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007; 74:338-343. (Pubitemid 47523077)
88. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278:9435-9440. (Pubitemid 36800434)
89. Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298:714-719. (Pubitemid 35356798)
90. Kogire M, Gomez G, Uchida T, et al. Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas 1992; 7:15-20.
91. Garg SK, Ritchie PJ, Moser EG, et al. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized doubleblind trial. Diabetes Obes Metab 2011; 13:137-143.
92. Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005; 146:984-991. (Pubitemid 40289284)
93. Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004; 279:23158-23165. (Pubitemid 38685621)
94. De FE, Mitro N, Gilardi F, et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003; 278:39124-39132. (Pubitemid 37221815)
95. Cariou B, Duran-Sandoval D, Kuipers F, Staels B. Farnesoid X receptor: a new player in glucose metabolism? Endocrinology 2005; 146:981-983. (Pubitemid 40289283)
96. Ma K, Saha P, Chan L, Moore D. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116:1102-1109.
97. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006; 103:1006-1011. (Pubitemid 43212212)
98. Watanabe M, Horai Y, Houten SM, et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 2011; 286:26913-26920.
99. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulinindependent activator of hepatic protein and glycogen synthesis. Science 2011; 331:1621-1624.
100. Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 2011; 13:729-738.
101. Wu X, Ge H, Lemon B, et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci USA 2009; 106:14379-14384.
102. Thomson AB, Keelan M. Feeding rats diets containing cheno-or ursodeoxycholic acid or cholestyramine modifies intestinal uptake of glucose and lipids. Digestion 1987; 38:160-170. (Pubitemid 18054707)
103. Schwartz SL, Lai YL, Xu J, et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord 2010; 8:179-188.
104. Watanabe M, Houten S, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439:484-489. (Pubitemid 43152840)
105. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10:167-177.
106. Brufau G, Bahr MJ, Staels B, et al. Plasma bile acids are not associated with energy metabolism in humans. Nutr Metab (Lond) 2010; 7:73.
107. Hay DW, Carey MC. Pathophysiology and pathogenesis of cholesterol gallstone formation. Semin Liver Dis 1990; 10:159-170. (Pubitemid 20299813)
108. Lavoie B, Balemba OB, Godfrey C, et al. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. J Physiol 2010; 588:3295-3305.
109. Moore JG. Circadian dynamics of gastric acid secretion and pharmacodynamics of H2 receptor blockade. Ann N Y Acad Sci 1991; 618:150-158.
110. Choi M, Moschetta A, Bookout AL, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12:1253-1255. (Pubitemid 44706926)
111. Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology 2000; 31:299-303. (Pubitemid 30078591)
112. Vrieze A, Holleman F, Zoetendal EG, et al. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 2010; 53:606-613.
113. Kootte RS, Vrieze A, Holleman F, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2011 (in press).